Sign in
CBIO Stock Price, Chart, Stats & News
Crescent Biopharma, Inc.
Save
496.29M
Market cap
–
Current P/E
–
Forward P/E
CBIO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 95.93% |
Operating margin | -340.05% |
Pretax margin | -336.02% |
Net margin | -340.85% |
Effective tax rate | -1.44% |
ROA | -58.74% |
ROE | -122.12% |
D/E | 0.01x |
Interest coverage ratio | -32.51x |
CBIO valuation
P/E | – |
P/S | 10.09x |
P/B | 7.78x |
P/CF | -69.93x |
P/FCF | -17.86x |
P/OCF | -69.93x |
PEG | -0.10x |
EV multiple | -4.26x |
About
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations.
Similar securities
Based on sector and market capitalization
Report issue